MassMutual Private Wealth & Trust FSB Buys 998 Shares of Johnson & Johnson $JNJ

MassMutual Private Wealth & Trust FSB increased its stake in Johnson & Johnson (NYSE:JNJ) by 0.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 205,088 shares of the company’s stock after buying an additional 998 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Johnson & Johnson were worth $31,327,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Highline Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the first quarter valued at approximately $49,000. Finally, Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $50,000. 69.55% of the stock is owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on JNJ shares. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. UBS Group increased their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Bank of America increased their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. Finally, Morgan Stanley increased their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $176.29.

Johnson & Johnson Stock Down 0.3%

Shares of JNJ stock opened at $177.49 on Tuesday. The company has a market capitalization of $427.46 billion, a price-to-earnings ratio of 18.98, a PEG ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The company’s fifty day moving average price is $171.25 and its 200-day moving average price is $161.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company’s revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.